Articles tagged with Drug Candidates
Researchers at Scripps Research Institute create Inforna, a technique to identify potent compounds targeting cancer-causing microRNAs. The method enables unprecedented targeting of disease-associated RNAs, offering a promising approach to designing novel anti-cancer drugs.
Researchers at VIB have identified a chemical substance that can disarm pathogenic bacteria, allowing them to treat urinary tract infections without destroying beneficial bacteria. This approach could provide a lower risk of resistance development and spread.
Researchers at Scripps Research Institute describe two new drug scaffolds that target the kappa opioid receptor, offering novel tools for treating pain, addiction, and other disorders. The compounds, called biased agonists, activate the receptor without recruiting beta arrestin, a molecule associated with depression.
A new study published in Blood journal presents a Swedish cancer drug candidate that inhibits tumour growth and prolongs survival in preclinical multiple myeloma models. The substance also kills multiple myeloma cells from cancer patients and overcomes resistance to clinically used drugs.
Wayne State University has licensed an intellectual property portfolio claiming composition of matter and methods of use of novel analogs and derivatives of the green tea flavonoid EGCG. The collaboration, involving Q. Ping Dou and Tak-Hang Chan, aims to develop novel approaches for cancer management and related conditions.
Researchers have identified a potential new drug for an inherited form of cancer with no known cure. The new compound, FRAX97, targets a protein family that plays a critical role in the development of Neurofibromatosis type 2. By inhibiting these kinases, tumor growth can be slowed and progression reduced by over 80%.
Scientists at Scripps Research Institute have developed a novel method to increase the potency of RNA treatments, resulting in a 2,500-fold improvement. The breakthrough enables precise targeting of disease-causing RNAs and could lead to more effective therapeutic agents.
Researchers at Karolinska Institutet developed a breakthrough method called CETSA to measure drug molecules' binding to target proteins. This enables more efficient development of new drugs and potential improvement in cancer treatments.
Researchers have rediscovered PARP inhibitors as potential treatments for BRCA-driven cancers, including ovarian and breast cancers. Four drug candidates are now set to enter Phase III clinical studies.
RG3039 demonstrates benefits in two SMA mouse models, extending survival and improving motor unit function. The drug also positively modifies motor unit pathologies and dysfunction, suggesting potential therapeutic benefit for SMA patients.
A synthetic compound ShK-186, derived from a sea anemone toxin, enhances metabolic activity and shows potential as a treatment for obesity. The compound selectively blocks the activity of a protein that promotes inflammation through the Kv1.3 potassium channel.
A new study offers promising hope for treating progeria by targeting the enzyme ICMT, which causes premature aging. Researchers have successfully tested an ICMT inhibitor on mice, reducing or blocking the development of progeria symptoms and increasing cell growth.
Scientists from VIB and KU Leuven discovered a new target molecule to develop a treatment against Alzheimer's disease. β-arrestin 2 plays a role in regulating the γ-secretase complex function and development of the disease. This research opens a new avenue for treating the disease at an early stage.
A new genetic sequencing tool, Next-Gen Lab-on-Bead, has been developed to speed up drug discovery and disease diagnostics. The technology uses next-generation sequencing to test millions of potential drug candidates simultaneously.
Researchers developed a medicated chewing gum formulation that improves patient compliance and faster absorption through the cheek, alleviating motion sickness sooner. Dimenhydrinate-based gum has great potential for commercialization and can be used to incorporate other active ingredients with objectionable taste into chewing gum.
Researchers at Washington State University have developed a new drug candidate that improves cognitive function in rats with Alzheimer's-like mental impairment by building new brain cell connections. The compound, called Dihexa, is stable and can cross the blood-brain barrier, allowing for pill-form administration.
Researchers found pyridomycin selectively kills Mycobacterium tuberculosis, including strains resistant to front-line drug isoniazid. The natural antibiotic targets the InhA enzyme, which is essential for bacterial cell wall production.
Christina Smolke, a Stanford bioengineer, has won a $2.5 million grant to explore using microbes to produce complex chemicals for advanced natural-product drugs. Her approach aims to transform the manufacturing scale and efficiency of microbial systems.
A novel approach to discover the first new tuberculosis (TB) combination drug regimen has cleared a major hurdle with a Phase II clinical trial finding it could kill more than 99 percent of patients' TB bacteria within two weeks. The results add to a growing body of evidence that this regimen could reduce treatment by more than a year ...
A new drug candidate, K11777, has shown promising results in treating hookworm infections with a single oral dose. The compound is under development to enter clinical trials and could provide a new solution for treating the disease if it proves safe and effective in humans.
A cross-disciplinary team at the University of Maryland has designed molecular containers that can hold drug molecules and increase their solubility up to nearly 3000 times. The discovery opens possibilities for rehabilitating drug candidates and improving successful drugs with better solubility.
Researchers from Notre Dame's Eck Institute for Global Health have developed a novel method using a gene chip to identify malaria drug resistance. This technology enables real-time response and modification of treatment strategies to combat emerging resistance.
The Wistar Institute is developing a new drug to treat Epstein-Barr virus-related cancers by targeting the dormant EBV virus in patient cells. The project aims to create a viable drug candidate with potential to save countless lives globally.
Scientists have identified small-molecule drug candidates that activate the TMEM16A channel, promoting salt and water movement in cells. The discovery could lead to new therapies for conditions such as cystic fibrosis, dry eye, and slow-transit constipation.
Researchers at Lund University have created a molecular image of a drug in human tissue using a special type of mass spectrometry. The technique allows for precise spatial distribution analysis, enabling the development of safer and more effective drug candidates.
Researchers have developed a new method to assess psychoactive compounds' effects on eye movements in mice, which can be used to predict efficacy and detect side effects. This approach shows promise for guiding more efficient drug development for brain-related conditions.
The elimination of the national kidney allocation policy has improved minority access to transplants, with minorities now transplanted in proportion to their representation on the waiting list. The overall number of deceased donor transplants rose 23%, with a larger increase for minorities.
The Gladstone Institutes have announced a Center for Comprehensive Alzheimer's Disease Research, which aims to develop therapies for Alzheimer's. The center will focus on identifying drug targets and candidates, leveraging collaborations with other institutions and companies.
A boron-based compound has shown safety and efficacy against stage 1 and 2 of the disease, with its oral formulation and short treatment duration promising for patient care. The collaboration between biotechs Anacor Pharmaceuticals and SCYNEXIS Inc., and not-for-profit DNDi, brings hope for a breakthrough in treating sleeping sickness.
Researchers from Monash University and international partners have developed a potential new malaria drug candidate targeting dihydroorotate dehydrogenase enzyme. The team's work has been hailed as significant in combating malaria, which kills up to one million people annually worldwide.
Tiny LNA-based compounds developed by Santaris Pharma A/S successfully inhibit entire microRNA families, targeting cancer, viral infections, and cardiovascular diseases. The high affinity and target specificity of these compounds enable functional inhibition without off-target effects.
The company's lead drug candidate, omecamtiv mecarbil, directly activates cardiac myosin, increasing cardiac function without changing contraction rates. This novel mechanism may provide a new therapeutic strategy for improving cardiac performance in patients with systolic heart failure.
A tiny polypeptide has been developed that can bind to target-seeking molecules, enhancing their properties and improving the efficiency of drug development. The concept presents a new approach to drug development, potentially allowing for rapid development of new drugs with reduced costs and time.
Researchers have identified a preclinical candidate that may slow the natural decline in memory associated with ageing. The new synthetic compound selectively blocks an enzyme involved in high levels of 'stress' steroid hormones, which are linked to memory loss.
A research team led by Scripps Research Institute has discovered a promising new drug candidate to treat malaria, which shows an attractive safety profile and potential for treatment in a single oral dose. The study's findings provide hope for the development of new treatments against this deadly disease.
The TB Alliance has made significant progress in developing new TB drugs, with three co-developed by the organization and its partners, and two others currently being tested through the Critical Path to TB Regimens (CPTR) initiative.
Scientists have identified a new approach to tackling human African trypanosomiasis (HAT), also known as sleeping sickness. A valid drug target has been found and leads for orally administered drugs have been identified, showing promise for effective treatment of the disease.
A team of researchers from Pitt and Walter Reed Army Institute of Research have identified compounds that hold promise for treating leishmaniasis, a parasitic infection affecting millions worldwide. The newly developed strategy, called HILCES, uses high-throughput screening to identify effective drug candidates.
The development of siRNA drugs is hindered by a strong immune response that can cause toxic side effects. Researchers are exploring mechanisms for inducing this response and strategies for minimizing its effects.
Researchers at LSTM and UoL aim to develop a new antimalarial drug that targets a novel enzyme in Plasmodium falciparum, potentially eliminating malaria symptoms. The project will use computational techniques and molecular modeling to design effective inhibitors.
A study by Gerry Stefanatos and team found that dextroamphetamine improved speech processing in patients with Broca's aphasia and Anomic aphasia, suggesting the drug may enhance brain repair and therapy outcomes.
VIB researchers found a way cells can detect nutrients via transceptors, similar to hormone signaling. This discovery offers promising possibilities for treating metabolic diseases by targeting newly discovered receptor proteins.
Researchers have identified five compounds that block the activity of the trypanosomal REL1 enzyme, which is crucial for the parasite's survival. The approach uses computational tools to predict the dynamics of proteins and test hundreds of compounds for their ability to inhibit the enzyme.
Researchers have created a new therapy for preventing heart failure by developing a highly selective drug that blocks the production of aldosterone. The compounds were synthesized and tested in cell cultures and rat models, showing promising results.
A new Web-based resource is being developed to provide molecular data needed for computer-aided drug design. The resource aims to improve the prediction of potential drug candidates and advance biomedical research.
Regeneron's ARCALYST (rilonacept) has been shown to effectively manage symptoms of Cryopyrin-Associated Periodic Syndromes (CAPS), a rare inherited disease. The treatment demonstrated an 84% improvement in overall symptom scores and high patient response rates.
Researchers isolated over two dozen novel compounds that could serve as backup anti-viral drugs against avian flu. These compounds showed potentially stronger or equal inhibition than current remedies, including Tamiflu and Relenza.
Researchers at Saint Louis University have made a breakthrough finding that a smallpox drug, hexadecyloxypropyl-cidofovir (CMX001), successfully targets adenovirus in animal models. CMX001 provided protection from the virus when administered prophylactically or therapeutically and reduced viral load to undetectable levels.
Research at Harvard University found that drugs approved on tight FDA deadlines are more likely to face later regulatory action for safety concerns. The study suggests that a more flexible approval protocol could improve drug safety and reduce rushed approvals.
Scientists at Sirtris developed potent SIRT1 activators, 1000 times more effective than resveratrol, to treat Type 2 Diabetes and age-related diseases. These findings hold promise for a new approach to treating metabolic and other diseases of aging.
A study by Jason Dyck at the University of Alberta found that a protein responsible for transporting fat into heart cells may be a key to preventing age-related decline in heart function. Genetically modified mice with this protein deficiency showed no accumulated fat in their hearts and outperformed normal aged mice on a treadmill test.
Contrave significantly reduced food intake in both lean and obese mice by targeting the ventral tegmental area, a key region of the reward pathway. The combination of bupropion and naltrexone resulted in a 94% reduction of food intake in obese mice, demonstrating potential for effective weight loss treatment.
Researchers create an array of magnetic-field sensors to detect tiny magnetic spheres, which can bind with cell receptors. This technology enables rapid evaluation of potential antiviral drugs and high-precision detection of cancer biomarkers.
Diarrheal diseases kill over 2 million children annually, and the Institute for OneWorld Health aims to combat this with novel anti-secretory drugs. The $46 million grant will support the development of new treatments to complement traditional approaches.
The University of North Carolina has received a $21.3 million grant from the Bill & Melinda Gates Foundation to develop new treatments for late-stage African sleeping sickness and visceral leishmaniasis. The project aims to create affordable therapies for diseases affecting hundreds of thousands of people in developing nations.
A promising new TB drug candidate, SQ109, has been cleared for Phase I clinical trials following a successful public-private partnership between NIAID and Sequella. Developed with extensive support from NIAID, SQ109 holds potential for treating the virtually untreatable disease XDR-TB.
Research demonstrates zebrafish as an efficient and effective animal model for assessing human cancer cells at various stages of tumorigenesis, with significant findings including conserved cell signaling mechanisms and the ability to visualize cell migration and angiogenesis formation in vivo.
A newly isolated compound, nostocarboline, has been shown to be a potent inhibitor of cholinesterase, a brain chemical linked to Alzheimer's disease progression. Its potency is comparable to an existing cholinesterase inhibitor, and it holds promise as a potential treatment for mild to moderate forms of the disease.
A new biochip tool called MetaChip can analyze drug candidates for toxicity and eliminate harmful ones before they advance to pre-clinical stages. The technology mimics the effects of metabolism in the human liver, enabling early detection of toxic compounds that could be difficult to predict or find with current testing methods.
Scientists at the University of Arizona have created melanotropin-based drugs with improved properties that can selectively target specific receptors. These compounds show promise in treating various conditions, including cancer, sexual dysfunction, and eating disorders.